Abstract
Mixed effect models are becoming common in analyzing data from clinical trials involving several measurements for each subject. However, designs using mixed effect models have not received as much attention. Data collected from first-time-in-human studies are frequently used for studying dose proportionality. Two design types were evaluated theoretically for a hypothetical study conducted at six doses evenly spaced on a log scale for a drug whose AUC-dose relationship can be described by a mixed effect power model. In sequential panel design, subjects receive consecutive doses and in alternate panel design, subjects receive nonconsecutive doses. Sample sizes required to characterize the AUC-dose relationship to the same level of precision by both designs were calculated at given inter- and intra-subject variabilities. The conclusion is that an alternate panel design always requires fewer subjects than a sequential panel design. In many common cases, less than half as many subjects are required.
Similar content being viewed by others
References
Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Inf J. 1995:29:1039–1048.
Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS® System for Mixed Models. Cary, NC: SAS Institute Inc.; 1996:139.
Julious S, Debamot AM. Why are pharmacokinetic data summarized by arithmetic means? J Biopharm Stat. 2000:10(1):55–71.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yin, Y., Chen, C. Optimizing First-Time-In-Human Trial Design for Studying Dose Proportionality. Ther Innov Regul Sci 35, 1065–1078 (2001). https://doi.org/10.1177/009286150103500404
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150103500404